Major bleeding necessitating discontinuation was seen in four patients (7%) whereas the other 21 patients (36.9%) died before completing 96 hours of therapy.
As a result, patients are put at increased risk for thromboembolism, bleeding, and premature discontinuation of anticoagulation therapy.
Climacteric complaints, side-effects, reason for discontinuation, bleeding patterns, lipid profile at baseline and 12 months of treatment were documented.
If the mother has fissures or bleeding nipples, temporary discontinuation of breast-feeding may be recommended, although thermal treatment (pasteurization or microwaving) of expressed milk before feeding the infant may be a safe alternative.
The most common reasons were bleeding complications (67/223 discontinuations; 30.0%) followed by non-bleeding side-effects (54/223; 24.2%), stable sinus rhythm (19/223; 8.5%), and worsening of renal function (18/223; 8.1%).
Most common reasons for treatment discontinuations were bleeding complications (30% of all discontinuations), followed by other side-effects (24.2%) and diagnosis of stable sinus rhythm (9.9%).
Continued anticoagulation is recommended for these patients unless pathological bleeding prompted discontinuation; coverage with another anticoagulant should be provided if patients discontinue for reasons other than pathological bleeding [ 11– 11].
For patients who experience major bleeding, treatment discontinuation and supportive care were recommended [ 54].
However, none of these superficial bleeding events led to discontinuation of the extracorporeal treatment.
No bleeding events led to discontinuation of eltrombopag dosing or study withdrawal, and none were considered by the investigator to be related to eltrombopag dosing.
The main reason for discontinuation is irregular bleeding.
